There is on-going development of generic EU CTD Dossier of Levetiracetam, tablets, 250/500/750/1000 mg.
DCP slot confirmed.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Levetiracetam (INN) is an anticonvulsant medication used to treat epilepsy. It is S-enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam.
Along with other anticonvulsants like gabapentin, it is also sometimes used to treat neuropathic pain.
Levetiracetam has recently been approved in the United Kingdom as a monotherapy treatment for epilepsy. It is also used in veterinary medicine for similar purposes.
Levetiracetam has potential benefits for other psychiatric and neurologic conditions such as Tourette syndrome, autism, and anxiety disorder, but its most serious adverse effects are behavioral and its benefit-risk ratio in these conditions is not well understood.
More details at: http://www.rxlist.com/keppra-drug.htm.
Read also at Pharmaceutical Licensing Network
Newer news items
|< Prev||Next >|
Regulatory Affairs for EU & USA